Publication

A randomized comparison of the fractionated versus single dose schedule of gemtuzumab ozogamicin at induction with determinants of benefit for older AML patients: UK NCRI AML18 Trial Results

Freeman, S. D.
; 
Thomas, A.
; 
Thomas, I.
; 
Vyas, P.
; 
Gilkes, A.
; 
Metzner, M.
; 
Jakobsen, N. A.
; 
Kennedy, A.
; 
Moore, A.
; 
Almuina, N. M.
... show 10 more
Citations
Altmetric:
Abstract
Authors
Freeman, S. D.
Thomas, A.
Thomas, I.
Vyas, P.
Gilkes, A.
Metzner, M.
Jakobsen, N. A.
Kennedy, A.
Moore, A.
Almuina, N. M.
Burns, S.
King, S.
Andrew, G. M.
Gallagher, K. M. E.
Sellar, R.
Cahalin, P.
Weber, D.
Dennis, Michael
Mehta, P.
Knapper, S.
Russell, N. H.
Affiliation
Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham
Description
Date
2022
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Freeman SD, Thomas A, Thomas I, Vyas P, Gilkes A, Metzner M, et al. A Randomized Comparison of the Fractionated Versus Single Dose Schedule of Gemtuzumab Ozogamicin at Induction with Determinants of Benefit for Older AML Patients: UK NCRI AML18 Trial Results. Blood. 2022 Nov;140. PubMed PMID: WOS:000893223200220.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/626108
Embedded videos